Zota Health Care Limited, founded in 2000, is an Indian pharmaceutical company focused on the development, manufacturing, and marketing of a wide variety of pharmaceutical, nutraceutical, and ayurvedic products. Its headquarters are located in Surat, Gujarat, India.
The company has obtained product registration licences for two items: Zotamet 1000 (Metformin Tablets BP 1000 mg), an antidiabetic medication, and CDTEL-40 (Telmisartan Tablets USP 40 mg), an angiotensin II antagonist. These licences were granted by the Department of Medicines and Medical Devices under the Ministry of Health of the Kyrgyz Republic, Kyrgyzstan.
The product registration licences are valid for five years and can be renewed upon expiry. Zota Health Care plans to start exporting these products to Kyrgyzstan in the near future.
Zotamet, one of Zota Health Care’s premier products, aims to provide effective care for diabetes mellitus. With the global rise of diabetes, the need for affordable and efficient antidiabetic medications has never been more pressing. The introduction of Zotamet in the Kyrgyzstan market seeks to fulfil this important demand by offering a dependable solution for patients facing challenges with blood sugar regulation.
This initiative is expected to enable thousands of patients to access advanced diabetes care, potentially enhancing their quality of life and alleviating the overall strain of the disease on Kyrgyzstan’s healthcare system.
As of 1:04 PM today, shares of Zota Health Care Ltd. were trading at ₹792.95 on the NSE.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Dec 30, 2024, 3:51 PM IST
We're Live on WhatsApp! Join our channel for market insights & updates